Urology
Volume 67, Issue 6 , Pages 1216-1223 , June 2006

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

  • Rui Fa Han

      Affiliations

    • Corresponding Author InformationReprint requests: Rui Fa Han, M.D., Tianjin Institute of Urologic Surgery, Genetic Room, Pingjiang Road, No. 23, Hexi District, Tianjin, China.
    • ,
  • Jian Gang Pan

Received 1 August 2005 ,Accepted 5 December 2005.

References 

  1. Richard J , Adrian PM , Donald L . Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer (a meta-analysis of the published results of randomized clinical trials) . J Urol . 2002;168:1964–1970
  2. Lichtenstein MJ , Mulrow CD , Elwood PC . Guidelines for reading case control studies . J Chron Dis . 1987;40:893–903
  3. de Reijke TM , Kurth KH , Sylvester RJ , et al.   Bacillus Calmette-Guérin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder (results of a European Organization for the Research and Treatment of Cancer–Genito-Urinary Group Phase III Trial) . J Urol . 2005;173:405–409
  4. Yumura Y , Oogo Y , Takase K , et al.   Results of adjuvant intravesical bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer . Hinyokika Kiyo . 2004;50:767–771
  5. Peyromaure M , Zerbib M . T1G3 transitional cell carcinoma of the bladder (recurrence, progression and survival) . BJU Int . 2004;93:60–63
  6. Kaasinen E , Wijkstrom H , Malmstrom PU , et al.   Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder (a Nordic study) . Eur Urol . 2003;43:637–645
  7. Librenjak D , Situm M , Eterovic D , et al.   Immunoprophylactic intravesical application of bacillus Calmette-Guérin after transurethral resection of superficial bladder cancer . Croat Med J . 2003;44:187–192
  8. Irie A , Uchida T , Yamashita H , et al.   Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence . Int J Urol . 2003;10:183–189
  9. Tong M , Yu LZ , Ding Y , et al.   Prevention of postoperative recurrence of human bladder carcinoma by intravesical instillation of immunotoxin, a clinical study . Zhonghua Yi Xue Za Zhi . 2003;83:201–203
  10. Hara I , Miyake H , Takechi Y , et al.   Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder . Int J Urol . 2003;10:19–24
  11. Shahin O , Thalmann GN , Rentsch C , et al.   A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer (recurrence, progression and survival) . J Urol . 2003;169:96–100
  12. Kaasinen E , Rintala E , Hellstrom P , et al.   Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma . Eur Urol . 2002;42:167–174
  13. Patard JJ , Rodriguez A , Leray E , et al.   Intravesical bacillus Calmette-Guérin treatment improves patient survival in T1G3 bladder tumours . Eur Urol . 2002;41:635–641
  14. Martinez-Pineiro JA , Flores N , Isorna S , et al.   Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer . BJU Int . 2002;89:671–680
  15. Kolodziej A , Dembowski J , Zdrojowy R , et al.   Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Guérin therapy (preliminary results) . BJU Int . 2002;89:620–622
  16. Chepurov AK , Murshudli EC , Mazo EB . Features of BCG-therapy in treating patients with superficial bladder cancer . Ter Arkh . 2002;74:70–72
  17. Sekine H , Ohya K , Kojima SI , et al.   Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guérin therapy for carcinoma in situ of the bladder . Int J Urol . 2001;8:483–486
  18. van der Meijden AP , Brausi M , Zambon V , et al.   Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder (a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial) . J Urol . 2001;166:476–481
  19. Tozawa K , Okamura T , Sasaki S , et al.   Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer . Urol Int . 2001;67:289–292
  20. Lamm DL , Blumenstein BA , Crissman JD , et al.   Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder (a randomized Southwest Oncology Group study) . J Urol . 2000;163:1124–1129
  21. Altay B , Girgin C , Kefi A , et al.   The best management of superficial bladder tumours (comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?) . Int Urol Nephrol . 2000;32:53–58
  22. Moyano Calvo JL , Ortiz Gamiz A , Romero Diaz A , et al.   The prevention of stage-T1 superficial bladder tumors with 27 mg. of BCG weekly over 6 weeks . Arch Esp Urol . 1999;52:760–768
  23. Malmstrom PU , Wijkstrom H , Lundholm C , et al.  Swedish-Norwegian Bladder Cancer Study Group   5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma . J Urol . 1999;161:1124–1127
  24. Witjes JA , Caris CT , Mungan NA , et al.   Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guérin versus mitomycin C alone in patients with superficial bladder cancer . J Urol . 1998;160:1668–1671
  25. Witjes JA , van der Meijden AP , Collette L , et al.  European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative (EORTC GU) Group and the Dutch South East Cooperative Urological Group   Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer . Urology . 1998;52:403–410
  26. Ayed M , Ben Hassine L , Ben Slama R , et al.   Results of BCG in the treatment of pTa and pT1 bladder tumors (evaluation of a long protocol using 75 mg of Pasteur strain BCG) . Prog Urol . 1998;8:206–210
  27. Jimenez-Cruz JF , Vera-Donoso CD , Leiva O , et al.   Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1) (multicenter trial comparing bacille Calmette-Guérin and interferon-alpha) . Urology . 1997;50:529–535
  28. Bohle A , Jcham D , Bock PR . Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer (a meta-analysis of the published results of randomized clinical trials) . Int Braz J Urol . 2002;28:585–586
  29. Sylvester RJ , van der Meijden AP , Witjes JA , et al.   Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder (a meta-analysis of the published results of randomized clinical trials) . J Urol . 2005;174:86–92

PII: S0090-4295(05)01768-1

doi: 10.1016/j.urology.2005.12.014

Urology
Volume 67, Issue 6 , Pages 1216-1223 , June 2006

Article Tools

* Image Usage & Resolution